Malondialdehyde levels in diabetic retinopathy patients: a systematic review and meta-analysis.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
05 Jun 2023
05 Jun 2023
Historique:
medline:
6
6
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
epublish
Résumé
It remains unclear whether circulating malondialdehyde (MDA) levels change in people with diabetic retinopathy (DR). This systematic review compared circulating MDA levels in diabetic people with and without DR. PubMed, Medline (Ovid), Embase (Ovid), and Web of Science were searched for case-control studies conducted before May 2022 in English that compared circulating MDA levels in people with and without DR. The following MeSH search terms were used: ("malondialdehyde" or "thiobarbituric acid reactive substances [TBARS]" or "lipid peroxidation" or "oxidative stress") and "diabetic retinopathy." Newcastle-Ottawa Quality Assessment Scale was used to evaluate the quality of the included studies. Random-effects pairwise meta-analysis pooled the effect size with standardized mean difference (SMD) and 95% confidence intervals (CIs). This meta-analysis included 29 case-control studies with 1680 people with DR and 1799 people with diabetes but not DR. Compared to people without DR, the circulating MDA levels were higher in those with DR (SMD, 0.897; 95% CI, 0.631 to 1.162; P < 0.001). The study did not identify credible subgroup effects or publication bias and the sensitivity analysis confirmed the robustness of the study. Circulating MDA levels are higher in people with DR compared to those without. Future comparative studies that use more specific methods are required to draw firm conclusions. PROSPERO; https://www.crd.york.ac.uk/PROSPERO/ ; No. CRD42022352640.
Sections du résumé
BACKGROUND
BACKGROUND
It remains unclear whether circulating malondialdehyde (MDA) levels change in people with diabetic retinopathy (DR). This systematic review compared circulating MDA levels in diabetic people with and without DR.
METHODS
METHODS
PubMed, Medline (Ovid), Embase (Ovid), and Web of Science were searched for case-control studies conducted before May 2022 in English that compared circulating MDA levels in people with and without DR. The following MeSH search terms were used: ("malondialdehyde" or "thiobarbituric acid reactive substances [TBARS]" or "lipid peroxidation" or "oxidative stress") and "diabetic retinopathy." Newcastle-Ottawa Quality Assessment Scale was used to evaluate the quality of the included studies. Random-effects pairwise meta-analysis pooled the effect size with standardized mean difference (SMD) and 95% confidence intervals (CIs).
RESULTS
RESULTS
This meta-analysis included 29 case-control studies with 1680 people with DR and 1799 people with diabetes but not DR. Compared to people without DR, the circulating MDA levels were higher in those with DR (SMD, 0.897; 95% CI, 0.631 to 1.162; P < 0.001). The study did not identify credible subgroup effects or publication bias and the sensitivity analysis confirmed the robustness of the study.
CONCLUSIONS
CONCLUSIONS
Circulating MDA levels are higher in people with DR compared to those without. Future comparative studies that use more specific methods are required to draw firm conclusions.
REGISTRATION
BACKGROUND
PROSPERO; https://www.crd.york.ac.uk/PROSPERO/ ; No. CRD42022352640.
Identifiants
pubmed: 37101358
doi: 10.1097/CM9.0000000000002620
pii: 00029330-202306050-00005
pmc: PMC10309507
doi:
Substances chimiques
Malondialdehyde
4Y8F71G49Q
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1321Informations de copyright
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
Kobrin Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14:179–183. doi: 10.1080/09286580701396720.
doi: 10.1080/09286580701396720
Steinmetz JD, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, Jonas JB, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 2021; 9:e144–e160. doi: 10.1016/S2214-109X(20)30489-7.
doi: 10.1016/S2214-109X(20)30489-7
Teo ZL, Tham Y-C, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 2021; 128:1580–1591. doi: 10.1016/j.ophtha.2021.04.027.
doi: 10.1016/j.ophtha.2021.04.027
Li J, Shi Q, Gao Q, Pan XF, Zhao L, He Y, et al. Obesity pandemic in China: epidemiology, burden, challenges, and opportunities. Chin Med J 2022; 135:1328–1330. doi: 10.1097/cm9.0000000000002189.
doi: 10.1097/cm9.0000000000002189
Cai XL, Wang F, Ji LN. Risk factors of diabetic retinopathy in type 2 diabetic patients. Chin Med J 2006; 119:822–826. doi: 10.1097/00029330-200605020-00005.
doi: 10.1097/00029330-200605020-00005
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376:124–136. doi: 10.1016/S0140-6736(09)62124-3.
doi: 10.1016/S0140-6736(09)62124-3
Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015; 122:1375–1394. doi: 10.1016/j.ophtha.2015.03.024.
doi: 10.1016/j.ophtha.2015.03.024
Wang Y, Zhai WL, Yang YW. Association between NDRG2/IL-6/STAT3 signaling pathway and diabetic retinopathy in rats. Eur Rev Med Pharmacol Sci 2020; 24:3476–3484. doi: 10.26355/eurrev_202004_20806.
doi: 10.26355/eurrev_202004_20806
Li X, Deng A, Liu J, Hou W. The role of Keap1-Nrf2-ARE signal pathway in diabetic retinopathy oxidative stress and related mechanisms. Int J Clin Exp Pathol 2018; 11:3084–3090.
Zhang L, Yu J, Ye M, Zhao H. Upregulation of CKIP-1 inhibits high-glucose induced inflammation and oxidative stress in HRECs and attenuates diabetic retinopathy by modulating Nrf2/ARE signaling pathway: an in vitro study. Cell Biosci 2019; 9:67doi: 10.1186/s13578-019-0331-x.
doi: 10.1186/s13578-019-0331-x
Dave A, Kalra P, Gowda BH, Krishnaswamy M. Association of bilirubin and malondialdehyde levels with retinopathy in type 2 diabetes mellitus. Indian J Endocrinol Metab 2015; 19:373–377. doi: 10.4103/2230-8210.152777.
doi: 10.4103/2230-8210.152777
Mondal LK, Bhaduri G, Bhattacharya B. Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus. Indian J Ophthalmol 2018; 66:535–540. doi: 10.4103/ijo.IJO_1121_17.
doi: 10.4103/ijo.IJO_1121_17
Sanz-González SM, García-Medina JJ, Zanón-Moreno V, López-Gálvez MI, Galarreta-Mira D, Duarte L, et al. Clinical and molecular-genetic insights into the role of oxidative stress in diabetic retinopathy: antioxidant strategies and future avenues. Antioxidants 2020; 9:1101doi: 10.3390/antiox9111101.
doi: 10.3390/antiox9111101
Verma MK, Singh SP, Alam R, Verma P. Comparative study on MDA, SOD and HBA1C Levels in patients of type 2 diabetes mellitus with retinopathy and without retinopathy. Int J Pharm Sci Res 2016; 7:4184–4190. doi: 10.13040/IJPSR.0975-8232.7(10).4184-90.
doi: 10.13040/IJPSR.0975-8232.7(10).4184-90
Fahmy R, Almutairi NM, Al-Muammar MN, Bhat RS, Moubayed N, El-Ansary A. Controlled diabetes amends oxidative stress as mechanism related to severity of diabetic retinopathy. Sci Rep 2021; 11:17670doi: 10.1038/s41598-021-96891-7.
doi: 10.1038/s41598-021-96891-7
Dai L, Wang Y, Liu Y, Wu Y. Correlation of serum LXA4 and VEGF levels with inflammatory factors and oxidative stress indexes in patients with diabetic retinopathy. Acta Med Mediterr 2021; 37:2843–2847. doi: 10.19193/0393-6384_2021_5_438.
doi: 10.19193/0393-6384_2021_5_438
Aldebasi YH, Mohieldein AH, Almansour YS, Almutairi BL. Dyslipidemia and lipid peroxidation of Saudi type 2 diabetics with proliferative retinopathy. Saudi Med J 2013; 34:616–622. doi: 10.1016/j.pop.2013.04.001.
doi: 10.1016/j.pop.2013.04.001
Kuppan K, Mohanlal J, Mohammad AM, Babu KA, Sen P, Das Undurti N, et al. Elevated serum OxLDL is associated with progression of type 2 Diabetes Mellitus to diabetic retinopathy. Exp Eye Res 2019; 186:107668doi: 10.1016/j.exer.2019.05.008.
doi: 10.1016/j.exer.2019.05.008
Roig-Revert MJ, Lleó-Pérez A, Zanón-Moreno V, Vivar-Llopis B, Marín-Montiel J, Dolz-Marco R, et al. Enhanced oxidative stress and other potential biomarkers for retinopathy in type 2 diabetics: beneficial effects of the nutraceutic supplements. Biomed Res Int 2015; 2015:408180doi: 10.1155/2015/408180.
doi: 10.1155/2015/408180
Shawki HA, Elzehery R, Shahin M, Abo-Hashem EM, Youssef MM. Evaluation of some oxidative markers in diabetes and diabetic retinopathy. Diabetol Int 2021; 12:108–117. doi: 10.1007/s13340-020-00450-w.
doi: 10.1007/s13340-020-00450-w
Choudhuri S, Roy PK, Mitra B, Sen S, Sarkar R, Das M, et al. Hyperlipidemia-mediated increased advanced lipoxidation end products formation, an important factor associated with decreased erythrocyte glucose-6-phosphate dehydrogenase activity in mild nonproliferative diabetic retinopathy. Can J Diabetes 2017; 41:82–89. doi: 10.1016/j.jcjd.2016.07.007.
doi: 10.1016/j.jcjd.2016.07.007
Vivian Samuel T, Jayaprakash Murthy DSK, Dattatreya, Suresh Babu P, Smilee Johncy S. Impaired antioxidant defence mechanism in diabetic retinopathy. J Clin Diagnostic Res 2010; 4:3430–33436.
Kurtul N, Bakan E, Aksoy H, Baykal O. Leukocyte lipid peroxidation, superoxide dismutase and catalase activities of type 2 diabetic patients with retinopathy. Acta Medica 2005; 48:35–38. doi: 10.14712/18059694.2018.26.
doi: 10.14712/18059694.2018.26
Gupta MM, Chari S. Lipid peroxidation and antioxidant status in patients with diabetic retinopathy. Indian J Physiol Pharmacol 2005; 49:187–192.
Losada M, Alio JL. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy. Doc Ophthalmol 1996; 93:223–229. doi: 10.1007/bf02569062.
doi: 10.1007/bf02569062
Sharma S, Saxena S, Srivastav K, Shukla RK, Mishra N, Meyer CH, et al. Nitric oxide and oxidative stress is associated with severity of diabetic retinopathy and retinal structural alterations. Clin Exp Ophthalmol 2015; 43:429–436. doi: 10.1111/ceo.12506.
doi: 10.1111/ceo.12506
Kundu D, Mandal T, Nandi M, Osta M, Bandyopadhyay U, Ray D. Oxidative stress in diabetic patients with retinopathy. Ann Afr Med 2014; 13:41–46. doi: 10.4103/1596-3519.126951.
doi: 10.4103/1596-3519.126951
Vidya D, Shekhar R, Prabodh S, Chowdary NVS, Das MC, Joji Reddy M. Oxidative stress in diabetic retinopathy. J Clin Diagnostic Res 2011; 5:994–997. doi: 10.1016/S0168-8227(00)81893-8.
doi: 10.1016/S0168-8227(00)81893-8
Khalili F, Vaisi-Raygani A, Shakiba E, Kohsari M, Dehbani M, Naseri R, et al. Oxidative stress parameters and keap 1 variants in T2DM: association with T2DM, diabetic neuropathy, diabetic retinopathy, and obesity. J Clin Lab Anal 2022; 36:e24163doi: 10.1002/jcla.24163.
doi: 10.1002/jcla.24163
Mandal LK, Choudhuri S, Dutta D, Mitra B, Kundu S, Chowdhury IH, et al. Oxidative stress-associated neuroretinal dysfunction and nitrosative stress in diabetic retinopathy. Can J Diabetes 2013; 37:401–407. doi: 10.1016/j.jcjd.2013.05.004.
doi: 10.1016/j.jcjd.2013.05.004
Gaonkar B, Prabhu K, Rao P, Kamat A, Rao Addoor K, Varma M. Plasma angiogenesis and oxidative stress markers in patients with diabetic retinopathy. Biomarkers 2020; 25:397–401. doi: 10.1080/1354750x.2020.1774654.
doi: 10.1080/1354750x.2020.1774654
Kumari S, Panda S, Mangaraj M, Mandal MK, Mahapatra PC. Plasma MDA and antioxidant vitamins in diabetic retinopathy. Indian J Clin Biochem 2008; 23:158–162. doi: 10.1007/s12291-008-0035-1.
doi: 10.1007/s12291-008-0035-1
Turk A, Nuhoglu I, Mentese A, Karahan SC, Erdol H, Erem C. The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde. Retina 2011; 31:602–608. doi: 10.1097/IAE.0b013e3181ed8cd1.
doi: 10.1097/IAE.0b013e3181ed8cd1
Longo-Mbenza B, Mvitu Muaka M, Masamba W, Muizila Kini L, Longo Phemba I, Kibokela Ndembe D, et al. Retinopathy in non diabetics, diabetic retinopathy and oxidative stress: a new phenotype in Central Africa? Int J Ophthalmol 2014; 7:293–301. doi: 10.3980/j.issn.2222-3959.2014.02.18.
doi: 10.3980/j.issn.2222-3959.2014.02.18
Gürler B, Vural H, Yilmaz N, Oguz H, Satici A, Aksoy N. The role of oxidative stress in diabetic retinopathy. Eye 2000; 14 (Pt 5):730–735. doi: 10.1038/eye.2000.193.
doi: 10.1038/eye.2000.193
El-Mesallamy HO, Rizk KA, Hashad IM. Role of oxidative stress, inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy. IIOAB J 2011; 2:91–97.
Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000; 23:234–240. doi: 10.2337/diacare.23.2.234.
doi: 10.2337/diacare.23.2.234
Icel E, Icel A, Mertoglu C, Tasli NG, Karakurt Y, Ucak T, et al. Serum SCUBE-1 levels in patients with diabetic retinopathy. Int Ophthalmol 2020; 40:859–865. doi: 10.1007/s10792-019-01249-8.
doi: 10.1007/s10792-019-01249-8
Kumari S, Pradhan T, Panda TK. Trace minerals and oxidative stress in diabetic retinopathy. Bangladesh J Med Sci 2014; 13:175–179. doi: 10.3329/bjms.v13i2.14963.
doi: 10.3329/bjms.v13i2.14963
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses In: Oxford. 2000; https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Ito F, Sono Y, Ito T. Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress: Oxidative stress in diabetes, atherosclerosis, and chronic inflammation. Antioxidants 2019; 8:72doi: 10.3390/antiox8030072.
doi: 10.3390/antiox8030072
Fritz KS, Petersen DR. An overview of the chemistry and biology of reactive aldehydes. Free Radic Biol Med 2013; 59:85–91. doi: 10.1016/j.freeradbiomed.2012.06.025.
doi: 10.1016/j.freeradbiomed.2012.06.025
Li G, Chen Y, Hu H, Liu L, Hu X, Wang J, et al. Association between age-related decline of kidney function and plasma malondialdehyde. Rejuvenation Res 2012; 15:257–264. doi: 10.1089/rej.2011.1259.
doi: 10.1089/rej.2011.1259
Choromańska B, Myśliwiec P, Dadan J, Maleckas A, Zalewska A, Maciejczyk M. Effects of age and gender on the redox homeostasis of morbidly obese people. Free Radic Biol Med 2021; 175:108–120. doi: 10.1016/j.freeradbiomed.2021.08.009.
doi: 10.1016/j.freeradbiomed.2021.08.009
Nakhjavani M, Esteghamati A, Nowroozi S, Asgarani F, Rashidi A, Khalilzadeh O. Type 2 diabetes mellitus duration: an independent predictor of serum malondialdehyde levels. Singapore Med J 2010; 51:582–585. doi: 10.1590/S1516-31802010000400013.
doi: 10.1590/S1516-31802010000400013
Solomon SD, Goldberg MF. ETDRS grading of diabetic retinopathy: still the gold standard? Ophthalmic Res 2019; 62:190–195. doi: 10.1159/000501372.
doi: 10.1159/000501372
Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges. Anal Biochem 2017; 524:13–30. doi: 10.1016/j.ab.2016.10.021.
doi: 10.1016/j.ab.2016.10.021
Mas-Bargues C, Escrivá C, Dromant M, Borrás C, Viña J. Lipid peroxidation as measured by chromatographic determination of malondialdehyde. human plasma reference values in health and disease. Arch Biochem Biophys 2021; 709:108941doi: 10.1016/j.abb.2021.108941.
doi: 10.1016/j.abb.2021.108941
Moselhy HF, Reid RG, Yousef S, Boyle SP. A specific, accurate, and sensitive measure of total plasma malondialdehyde by HPLC. J Lipid Res 2013; 54:852–858. doi: 10.1194/jlr.D032698.
doi: 10.1194/jlr.D032698